Page last updated: 2024-09-05

lapatinib and amsacrine

lapatinib has been researched along with amsacrine in 1 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(amsacrine)
Trials
(amsacrine)
Recent Studies (post-2010) (amsacrine)
1,9193051,4421,293127120

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)amsacrine (IC50)
Solute carrier family 22 member 1 Homo sapiens (human)5
Multidrug resistance-associated protein 4Homo sapiens (human)7.43
DNA topoisomerase 2-alphaHomo sapiens (human)5.47
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)5
DNA topoisomerase 2-betaHomo sapiens (human)1.88
Aldehyde oxidaseHomo sapiens (human)3.2
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.2095
Aldehyde oxidase 1 Rattus norvegicus (Norway rat)6.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J1

Other Studies

1 other study(ies) available for lapatinib and amsacrine

ArticleYear
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:12

    Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines

2013